Namespaces
SARS-CoV-2 Omicron variant
(Redirected from B.1.1.529)
SARS-CoV-2 Omicron variant is a variant of the SARS-CoV-2 virus, which is responsible for the COVID-19 pandemic. It was first identified in Botswana in November 2021 and was subsequently designated as a variant of concern by the World Health Organization (WHO) due to its large number of mutations and potential implications for global public health.
Origin and identification[edit | edit source]
The Omicron variant was first identified through genomic sequencing in Botswana in November 2021. It was subsequently reported to the WHO, which designated it as a variant of concern on 26 November 2021. The variant has been named 'Omicron' as per the WHO's policy of naming variants after letters of the Greek alphabet.
Characteristics[edit | edit source]
The Omicron variant is characterized by a large number of mutations, particularly in the spike protein of the virus, which is the target of most COVID-19 vaccines. Preliminary studies suggest that these mutations may increase the transmissibility of the virus and potentially affect the efficacy of vaccines, although further research is needed to confirm these findings.
Impact[edit | edit source]
The emergence of the Omicron variant has led to increased concern among global health authorities due to its potential to spread rapidly and evade immunity from vaccination or previous infection. However, it is currently unclear whether the variant is associated with more severe disease or increased mortality.
Response[edit | edit source]
In response to the emergence of the Omicron variant, many countries have implemented travel restrictions and increased surveillance and testing efforts. Vaccine manufacturers are also studying the variant and assessing the need for updated vaccines.
See also[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD